Two more Big Phar­ma CEOs en­joyed hefty rais­es in 2018, leav­ing the in­dus­try’s on­ly ma­jor league fe­male chief in ...

7 years ago
People

WuXi AppTec re­cruits new CMO; Em­bat­tled Alk­er­mes makes case for ex­pand­ed use of schiz­o­phre­nia drug Aris­ta­da

7 years ago
News Briefing

Two Re­pub­li­can law­mak­ers feel 'oblig­ed' to warn drug­mak­ers that De­mo­c­rat col­league Cum­mings is pur­port­ed­ly out to ...

7 years ago
Pharma

Pe­ter Hecht re­cruits Bay­er/Shire vet An­dreas Busch for a top R&D post at his $175M biotech spin­out

7 years ago
People

BeiGene lines up a next-gen CT­LA-4 to com­ple­ment its PD-1 pil­lar in new deal worth up to $270M

7 years ago
R&D
Pharma

Pox­el, part­ner Sum­it­o­mo Dainip­pon taste suc­cess in first piv­otal test for oral di­a­betes drug

7 years ago
R&D

Af­ter re­vamp­ing R&D in a glob­al shake­up, Bay­er prep­ping new labs for an ex­pan­sion in can­cer re­search at MIT

7 years ago
R&D

Phase­Bio touts 'break­through' badge for blood­thin­ner re­ver­sal agent li­censed from As­traZeneca, shares leap

7 years ago
Pharma

It’s a sell­er’s world in biotech M&A, and No­var­tis CEO Vas Narasimhan has his check book out and pen ready

7 years ago
Deals

Vi­iV's Dova­to wins speedy US ap­proval with PRV, em­pow­er­ing GSK to mus­cle in­to Gilead­'s HIV em­pire

7 years ago
Discovery

FDA snubs Zo­genix's an­ti-seizure drug, not hap­py with some slop­py, in­ad­e­quate R&D work

7 years ago
R&D

Unit­ed kills its PhI­II PAH drug af­ter it fails Ty­va­so com­bo study

7 years ago
R&D

TKI biotech lays out plans to raise about $125M in IPO; Hookipa sets terms for up­sized $100M IPO

7 years ago
News Briefing

Bat­tered and out of op­tions, His­to­gen­ics turns to eye drug de­vel­op­er Ocu­gen for re­verse merg­er

7 years ago
Deals
Pharma

Can Tre­vi make it through the IPO win­dow with an old opi­oid that failed their key PhII?

7 years ago
Financing

Cel­gene, Ac­celeron sub­mit FDA ap­pli­ca­tion for billed block­buster lus­pa­ter­cept — will they get pri­or­i­ty re­view?

7 years ago
Pharma

Go­ing gang­busters: The top 20 biotech plat­form deals by up­front cash

7 years ago
Pharma

Tapped as Kymab CEO, Si­mon Sturge jumps back in­to biotech pond as Dave Chiswell steps aside

7 years ago
People

An­oth­er play­er in the gene ther­a­py field is gun­ning for the Duchenne MD crown — and here’s what they're bet­ting ...

7 years ago
Bioregnum
Cell/Gene Tx

At a cool $1B-plus in up­front, eq­ui­ty and ear­ly-stage cash, Re­gen­eron ties a block­buster R&D part­ner­ship knot with ...

7 years ago
R&D
Pharma

Rat study sug­gests Al­ler­gan's failed an­ti­de­pres­sant ra­pastinel may work as opi­oid ad­dic­tion treat­ment

7 years ago
R&D
Discovery

Bay­er re­ports cy­ber at­tack point­ed to Chi­nese hack­ers; FDA pro­longs re­view of Dai­ichi Sanky­o's AML drug

7 years ago
News Briefing

Out­side re­view con­firms top Memo­r­i­al Sloan Ket­ter­ing ex­ec­u­tives flout­ed con­flicts-of-in­ter­est poli­cies — re­port

7 years ago
People

Peer Re­view: Plot­ting US moves, Zealand Phar­ma poach­es Al­ny­lam's Em­manuel Du­lac as new CEO

7 years ago
Peer Review
First page Previous page 944945946947948949950 Next page Last page
A service from the Financial Times